BORDSFORD Project

BOaRD expert Screening FOR Dysimmunity

Many patients with neuropsychiatric disorders have positive inflammatory markers but with impossibility of highlighting a specific pathologic auto-antibody, making current techniques insufficient to respond to clinicians.

A subgroup of patients with pharmacoresistant unexplained neuropsychiatric symptoms, could benefit from the detection of auto antibodies and adapted immunomodulatory therapy where appropriate.

BORDSFORD meets the goal to set a functional platform called **ImmunOptiC** in order to detect the presence of autoantibodies and in the same time measure their pathogenicity.

We build a translational project with a **board expert of clinicians and searchers** to explore the relevance of dysimmunity diagnosis in medical care. We plan to respond to the urgent technological and clinical need by setting a unique multiscale analysis platform in order to provide clinicians a robust, high-sensitivity, and functional outcome about autoantibodies.

Our collective effort gather experts from clinical services and from fundamental research labs, building a unique platform for detection with clinical expertise.

In terms of public health, the optimization, through fundamental research, of a reliable, reproducible technique that can be applied to large populations, represents an indispensable preliminary work for the harmonization of international techniques worldwide for the detection of autoimmunity.

Frédéric Villéga (MD, MSc) Neuropediatrician
provides the interface between the clinic and basic research

Laurent Groc (PhD) Deputy Director of Interdisciplinary Institute of Neurosciences
Team leader, manager of « ImmunOptiC »

Delphine Bouchet (PhD) Laboratory manager
in charge of basic research organization

Constance Manso (MSc) industry management major
in charge of technical biology experiment

Julien Dupuis (PhD) researcher as an Inserm investigator
in charge of basic research possibilities

Patrick Blanco (MD, PhD) Clinician expert for Dysimmunity
manages the final Biological Diagnosis

Cécile Contin-Bordes (PhD) Biologist expert for Dysimmunity
in charge of final Biological Diagnosis

Jérôme Honnorat (MD, PhD) Clinician expert for Dysimmunity
in charge of Ressource Center for auto-immune encephalitis

Kumaran Deiva (MD, PhD) Clinician expert for Dysimmunity
in charge of Ressource Center for inflammatory diseases

Nicolas Pineau (PhD) industry management major
lead the commercialization effort

Charlotte Terraz (Jurist)
in charge of medico-legal issues

Caroline Bouissoux, Océane Zaghet (Clinical research associates)
in charge of clinical data

Anne Gimbert (PharmD)
in charge of Clinical Research Trial

Isabelle Pellegrin (MD, PhD) In charge of Biological Resource Center
allows the biological collection of samples

SPARK VALUE: We hope to gain vital translational research know-how from experienced SPARK mentors, broaden our networks and expand them internationally, and learn from our peer SPARKees and similar projects from earlier patches. SPARK is a unique opportunity to develop our link with industries to enter in the competitive landscape of the medical diagnosis.

SPARK
BORDEAUX